Find information on thousands of medical conditions and prescription drugs.

Colistin

Colistin (polymyxin E) is a polymyxin antibiotic produced by certain strains of Bacillus polymyxa var. colistinus. Colistin is a mixture of cyclic polypeptides colistin A and B. Colistin is effective against Gram-negative bacilli, except Proteus. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Administration

Colistin is used as a sulphate or as sulphomethylated form, colistimethate. Colistin sulphate tablets are used to treat intestinal infections, or to suppress colon flora. Colistin sulphate is also used as topical creams, powders, and otic solutions. Colistimethate is used for parenteral administration, and also as an aerosol to treat pulmonary infections.

Mode of action

Colistin is polycationic and has both hydrophobic and lipophilic moieties. These interact with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal.

Pharmacokinetics

The absorption of colistin from the gastrointestinal tract is very poor. The main elimination route of colistin is through renal excretion.

Read more at Wikipedia.org


[List your site here Free!]


Melioidosis in tsunami survivors
From Emerging Infectious Diseases, 10/1/05 by Eugene Athan

To the Editor: A tsunami devastated coastal areas of the Indian Ocean rim in December 2004. Of the affected countries, more than half of the [approximately equal to] 300,000 deaths occurred in the Aceh Province of Indonesia, close to the epicenter of the earthquake near northern Sumatra. Infrastructure, including medical and laboratory facilities, in this region was severely damaged. Of >1,000,000 survivors, >500,000 likely were injured. Most injuries were from trauma, but a substantial number were caused by aspiration of, or immersion in, saltwater that may have been contaminated by soil, sewage, or other environmental sources.

Melioidosis, caused by the saprophytic gram-negative bacillus Burkholderia pseudomallei, is endemic in Southeast Asia and northern Australia. Most cases have been found in northeastern Thailand, Singapore, and northern Australia. Melioidosis has been reported only sporadically from Indonesia and mainly in returning travelers (1-3).

In the context of acute medical relief efforts to the town of Banda Aceh, we report on 10 patients with pneumonia, including 4 patients with culture-confirmed melioidosis, after their immersion in contaminated saltwater during the tsunami. Clinical and laboratory services were reestablished on January 3, 2005, at Fakinah Hospital and on January 13, 2005, at Zainoel Abidin Hospital by the relief teams. Patients were identified opportunistically; details of treatment and outcome were reviewed retrospectively. Cultures were taken when clinically indicated and when specimens were available. Sputum cultures were plated onto horse blood agar, cystine lactose electrolyte-deficient agar, Haemophilus agar, and colistin/ nalidixic acid blood agar incubated in a candle jar at 35[degrees]C for [less than or equal to] 3 days. Colonies suspicious for B. pseudomallei were subcultured to B. cepacia-selective media (Oxoid, Adelaide, South Australia, Australia). Blood cultures and screening cultures of throat and rectum specimens were not performed routinely. Isolates of B. pseudomallei and characteristic antimicrobial drug susceptibilities were confirmed with API20NE (bioMerieux, Marcy l'Etoile, France).

From January 3 to January 28, 2005, a total of 10 cases of postimmersion pneumonia were identified. All patients were <18 years of age and previously well; 6 were male. No cases were epidemiologically linked to others. The patients were treated 10-35 days after the tsunami. Eight had bilateral alveolar opacities on chest radiograph; 3 also had empyema. Clinical, radiologic, and microbiologic details are summarized in the online Table (Available from http://www.cdc.gov/ncidod/EID/vol 11 no 10/05-0740.htm#table).

The sputum cultures of 4 patients were positive for B. pseudomallei. Except posttsunami exposure, none had risk factors for melioidosis, including diabetes, renal failure, or thalassemia. Other co-isolated organisms included Pseudomonas aeruginosa and Klebsiella sp.; 2 patients who did not have cultures taken had cavitatory lung disease. All patients with melioidosis were treated with meropenem, and all but 1 clinically improved in the hospital.

This is the second report of melioidosis from within Indonesia (1) and the second published report of melioidosis after the tsunami disaster (4). Cases from this event were included in a preliminary communication (5). However, exported cases of melioidosis from Indonesia, as well as the neighboring countries of Singapore and Malaysia, have been reported previously (2,3), a likely indication that this infection is underrecognized in Indonesia. Melioidosis has also been reported in tsunami survivors from Sri Lanka (4) and Thailand.

A striking feature of this event is the lack of predisposing factors and the young age of the patients. This feature likely represents the unique mode of acquisition and magnitude of the infecting inoculum, as well as the vulnerability of children to near drowning after flooding. One third of the patients had empyema, which reflects both the severity of pulmonary disease and delay in receiving medical care. Undoubtedly, a substantial selection bias occurred by including only patients who sought hospital treatment, and this is suggested by the low death rate. Melioidosis, acquired after near drowning, has been associated with a short incubation period and severe disease. However, patients who had melioidosis before medical aid arrived in the region would likely have died. Patients with longer incubation periods also may have acquired melioidosis through contaminated wounds with subsequent hematogenous dissemination.

Medical services to the region were by no means comprehensive during this time. Many other patients with postimmersion pneumonia and melioidosis may have been overlooked, both during the study (for persons who were not treated or if cultures were not taken) and afterwards; the incubation period of melioidosis may be [less than or equal to] 62 years. A further limitation is the lack of denominator data because no reliable records were kept on hospital admissions, and the exact number of survivors is not yet known. Conflicting data are found on the accuracy of the API20NE test kit used to identify bacteria in this study (6-9), but we believe that the clinical features and microbiologic findings suggest melioidosis.

This report confirms that B. pseudomallei exists in the Aceh Province of Indonesia and that melioidosis and gram-negative pneumonia may complicate saltwater immersion in this region. After near drowning incidents, melioidosis is characterized by severe pulmonary disease, including pleural effusions. Clinicians worldwide should be mindful that melioidosis in tsunami survivors may appear many years after exposure.

Acknowledgments

We thank Rus Munander; colleagues who participated in acute medical relief efforts in Banda Aceh; Geoff Hogg; Emergency Management Australia; Queensland Health; Queensland Ambulance Service; our colleagues who supported us at home; and Diana Huis in 't Velt who translated the Dutch case report.

The Australian Agency for International Development and the Australian Department of Foreign Affairs and Trade provided support for relief efforts.

References

(l.) Snijders EP. Melioidosis op Java. Nederlands. Tijdschr Geneeskd. 1933;77: 560-1.

(2.) Schindler N, Calligaro KD, Dougherty M J, Diehl J, Modi KH, Braffman MN. Melioidosis presenting as an infected intrathoracic subclavian artery pseudoaneurysm treated with femoral vein interposition graft. J Vasc Surg. 2002;35:569-72.

(3.) Dance DA, Smith MD, Aucken HM, Pitt TL. Imported melioidosis in England and Wales. Lancet. 1999;353:208.

(4.) Nieminen T, Vaara M. Burkholderia pseudomallei infections in Finnish tourists injured by the December 2004 tsunami in Thailand. Euro Surveill. 2005;10.

(5.) Allworth AM. Tsunami lung: a necrotising pneumonia in survivors of the Asian tsunami. Med J Aust. 2005; 182:364.

(6.) Glass MB, Popovic T. Preliminary evaluation of the API 20NE and RapID NF plus systems for rapid identification of Burkholderia pseudomallei and B. mallei. J Clin Microbiol. 2005;43:479-83.

(7.) Inglis TJ, Chiang D, Lee GS, Chor-Kiang L. Potential misidentification of Burkholderia pseudomallei by API 20NE. Pathology. 1998;30:62-4.

(8.) Lowe P, Engler C, Norton R. Comparison of automated and nonautomated systems for identification of Burkholderia pseudomallei. J Clin Microbiol. 2002;40:4625-7.

(9.) Dance DA, Wuthiekanun V, Naigowit P, White NJ. Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 20NE. J Clin Pathol. 1989;42:645-8.

Eugene Athan,* Anthony M. Allworth, [dagger] Catherine Engler, [double dagger] Ivan Bastian, [section] and Allen C. Cheng * [paragraph]

* The Geelong Hospital, Geelong, Victoria, Australia; [dagger] Royal Brisbane Hospital, Brisbane, Queensland, Australia; [double dagger] Queensland Health Pathology Services, Townsville, Queensland, Australia; [section] Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia; and [paragraph] Menzies School of Health Research, Darwin, Northern Territory, Australia

Eugene Athan, Anthony M. Allworth, Catherine Engler, and Ivan Bastian participated in medical relief efforts, collected data, and contributed to writing this article. Allen C. Cheng analyzed the results and wrote the article.

Address for correspondence: Eugene Athan, Department of Infectious Diseases, The Geelong Hospital, Barwon Health, Ryrie St, Geelong 3220, Australia; fax: 61-3-5260-3040; email: eugene@barwonhealth.org.au

COPYRIGHT 2005 U.S. National Center for Infectious Diseases
COPYRIGHT 2005 Gale Group

Return to Colistin
Home Contact Resources Exchange Links ebay